

Liver sinusoidal endothelial cells: Physiology and role in liver diseases

Johanne Poisson^{1,2,†}, Sara Lemoine^{3,4,†}, Chantal Boulanger^{1,2}, François Durand^{5,6,7},
Richard Moreau^{5,6,7}, Dominique Valla^{5,6,7}, Pierre-Emmanuel Rautou^{1,2,5,6,7,*}

Keywords: Liver sinusoidal endothelial cells; Capillarization; Endothelial dysfunction; Cirrhosis; Liver regeneration; Angiogenesis; Drug delivery system; Endothelium.

Received 24 May 2016; received in revised form 5 July 2016; accepted 7 July 2016

Summary

Liver sinusoidal endothelial cells (LSECs) are highly specialized endothelial cells representing the interface between blood cells on the one side and hepatocytes and hepatic stellate cells on the other side. LSECs represent a permeable barrier. Indeed, the association of 'fenestrae', absence of diaphragm and lack of basement membrane make them the most permeable endothelial cells of the mammalian body. They also have the highest endocytosis capacity of human cells. In physiological conditions, LSECs regulate hepatic vascular tone contributing to the maintenance of a low portal pressure despite the major changes in hepatic blood flow occurring during digestion. LSECs maintain hepatic stellate cell quiescence, thus inhibiting intrahepatic vasoconstriction and fibrosis development. In pathological conditions, LSECs play a key role in the initiation and progression of chronic liver diseases. Indeed, they become capillarized and lose their protective properties, and they promote angiogenesis and vasoconstriction. LSECs are implicated in liver regeneration following acute liver injury or partial hepatectomy since they renew from LSECs and/or LSEC progenitors, they sense changes in shear stress resulting from surgery, and they interact with platelets and inflammatory cells. LSECs also play a role in hepatocellular carcinoma development and progression, in ageing, and in liver lesions related to inflammation and infection. This review also presents a detailed analysis of the technical aspects relevant for LSEC analysis including the markers these cells express, the available cell lines and the transgenic mouse models. Finally, this review provides an overview of the strategies available for a specific targeting of LSECs.

© 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

The vascular endothelium, representing the interface between blood and other tissues, is not only a physical barrier, but contributes to different physiological and pathological processes, including hemostasis/thrombosis, metabolites transportation, inflammation, angiogenesis and vascular tone [1]. Liver sinusoidal endothelial cells (LSECs) form the wall of the liver sinusoids and represent approximately 15 to 20% of liver cells but only 3% of the total liver volume [2]. LSECs are highly specialized endothelial cells. They have a discontinuous architecture meaning that fusion of the luminal and abluminal plasma membrane occurs at other sites than cell junctions, in areas called 'fenestrae'. This review focuses on the role of LSECs in physiological conditions and their involvement in liver diseases.

LSECs in the normal liver

Formation of sinusoids during embryogenesis

As illustrated in Fig. 1, an early structural differentiation of hepatic sinusoids occurs between gestational weeks 5 and 12 in human embryos [3]. During that period, LSECs gradually lose cell markers of continuous endothelial cells including platelet endothelial adhesion molecule-1 (PECAM-1, also called cluster of differentiation (CD)31), CD34 and 1F10 antigen, and acquire markers of adult sinusoidal cells including CD4, CD32 and the intracellular adhesion molecule-1 (ICAM-1). This differentiation of LSECs is regulated by hepatoblasts, both via the vascular endothelial growth factor (VEGF) they release and via direct intercellular interactions [4,5].

¹INSERM, UMR-970, Paris Cardio-vascular Research Center – PARCC, Paris, France;

²Université Paris Descartes, Sorbonne Paris Cité, Paris, France;

³INSERM, UMRS 938, Centre de Recherche Saint-Antoine, Université Pierre et Marie Curie Paris 6, Paris, France;

⁴Service d'hépatologie, Hôpital Saint-Antoine, APHP, Paris, France;

⁵Service d'hépatologie, DHU Unity Hôpital Beaujon, APHP, Clichy, France;

⁶INSERM, UMR-1149, Centre de Recherche sur l'inflammation, Paris-Clichy, France;

⁷Université Denis Diderot-Paris 7, Sorbonne Paris Cité, 75018 Paris, France

[†] These authors contributed equally as joint first authors.

* Corresponding author. Address: Service d'Hépatologie, Hôpital Beaujon, 100 Boulevard du Général Leclerc, 92110 Clichy, France. Tel.: +33 1 40 87 52 83; fax: +33 1 40 87 54 87. E-mail address: pierre-emmanuel.rautou@inserm.fr (P.-E. Rautou).

The embryological origin of LSECs is still a matter of debate. Initial observational studies described capillaries progressively surrounded by growing cords of hepatoblasts in the septum transversum, suggesting that LSECs derive from the septum transversum mesenchyme, a part of the mesoderm [3,6,7]. However, recent cell lineage experiments performed in mice showed that the septum transversum gives rise to mesothelial cells, hepatic stellate cells, portal fibroblasts, and perivascular mesenchymal cells, but not to LSECs [8]. A part of LSECs rather derives from a common progenitor to endothelial and blood cells, called the “hemangioblast”, as attested by overlapping expression of hematopoietic and endothelial cell markers by LSECs and by fate tracing experiments [9–14]. These progenitor cells form veins crossing the septum transversum, i.e., vitelin veins [15], umbilical veins or cardinal veins and then LSECs [16,17]. Another part of LSECs derives from the endocardium of the sinus venosus, a compartment of the primitive cardiac tube [18]. These two embryological origins might explain the heterogeneity of the markers expressed by LSECs in adults.

LSECs renewal

Although specific data are lacking, we can speculate that in a physiological state LSECs are quiescent, i.e., with a low proliferation rate and a long life span, similar to endothelial cells from large vessels [19]. LSECs renewal differs in physiological and in pathological conditions. Three cell types contribute to LSEC renewal, namely mature LSECs, intrahepatic or resident sinusoidal endothelial cell progenitors, and bone marrow derived sinusoidal endothelial cell progenitors [20]. Mature LSECs can self-proliferate in normal conditions, when stimulated with growth factors such as VEGF and FGF (fibroblast growth factor) [20,21]. Resident sinusoidal endothelial cell progenitors represent 1 to 7% of the LSECs of a normal rodent liver and probably contribute to LSECs regeneration [20]. Bone marrow derived sinusoidal endothelial cell progenitors do not participate in LSEC turnover in a normal liver [22]. By contrast, after liver injury, these cells are the main drivers of liver regeneration [20,22]. Indeed, a subtoxic dose of monocrotalin, a toxic agent for LSECs, elicits liver injury only when bone marrow is suppressed. In addition, infusion of bone marrow cells after a toxic dose of monocrotalin almost fully corrects liver lesions [23].

Hepatic blood flow regulation

Liver sinusoids have a dual blood supply, receiving blood flow from the portal vein (70%) and the hepatic artery (30%) [24]. Blood pressure equalizes in the sinusoid and blood is then drained into the hepatic veins and the inferior vena cava. Despite major

circadian changes in hepatic blood flow due to digestion, hepatic venous pressure gradient remains at 4 mmHg or less in a normal individual, attesting a fine regulation of hepatic vascular tone [25]. Intrahepatic shear stress is recognized as a main driver of hepatic blood flow regulation [26]. Shear stress is a frictional force applied by blood flow on endothelial surface [26]. It is proportional to flow intensity and to blood viscosity and inversely proportional to the cubic radius of the vessel [26]. Intrahepatic shear stress has never been directly measured in human or animal. Its evaluation is indeed difficult since the radius of sinusoids is very small and varies within the liver. Moreover, viscosity is hard to estimate in this specific area and also varies with hemodilution. In normal conditions, in the liver like in other vascular beds, the endothelium is able to generate vasodilator agents in response to increased shear stress in order to attenuate the increase in blood pressure. The loss of this property is called endothelial dysfunction. An endothelial specific transcription factor induced by prolonged shear stress, called Kruppel-like factor 2 (KLF2) mediates this effect of shear stress [27]. KLF2 induces the endothelial upregulation of vasodilating agents including nitric oxide (NO) [28] (Fig. 2). Shah and colleagues previously demonstrated that LSECs are the main source of NO in the normal liver through endothelial nitric oxide synthase (eNOS) activation by shear stress [29]. KLF2 also induces the downregulation of vasoconstrictive molecules including endothelin-1 [28]. Other molecules released by LSECs regulating blood flow include the vasodilating agent carbon monoxide (CO) and the metabolites of the cyclooxygenase (COX) pathway (thromboxane A₂, Prostacyclin) [30]. All these molecules act in a paracrine manner on hepatic stellate cells localized in the space of Disse [31]. Healthy LSECs maintain hepatic stellate cell quiescence, thus inhibiting their vasoconstrictive effect [34]. The concept that hepatic stellate cell activation induces sinusoid constriction is based on their expression of molecules found in smooth muscle cells including α SMA, on their position wrapped around the exterior of LSECs and on the *ex vivo* observation of their ability to contract [32,33]. Although still controversial, LSEC could also regulate blood flow by swelling, thus creating an inlet and an outlet sphincter [32]. Kupffer cells possess contractile proteins as well, but their role in the regulation of hepatic blood flow remains controversial [32]. In contrast to most vascular beds where blood flow is mostly regulated by smooth muscle cells, in the liver, smooth muscle cells play a limited role since, although present in hepatic arterioles, they are only found in limited numbers in portal venules [32].

LSECs, a selective barrier

LSECs are positioned at an interface. On their sinusoidal side, they are exposed to the highly

Key point

In a normal liver, differentiated LSECs are gatekeepers of fibrogenesis by maintaining hepatic stellate cells in their inactivated state. LSECs regulate sinusoidal blood flow through their action on hepatic stellate cells and thus maintain a low portal pressure.




Fig. 1. Formation of sinusoids during human embryogenesis. (A) Frontal section of an embryo showing the formation of an outgrowth of the foregut (endoderm), called the liver primordium, which extends into the septum transversum (mesoderm), in which blood vessels are developing. V, ventral; D, dorsal. (B) Transversal section of the embryo showing the liver primordium (i.e., hepatoblasts arranged in thick cords separated by vascular spaces) growing into the septum transversum. The hepatic sinusoids are progressively established. First, the endothelial lining is continuous with a basement membrane (pink region) and no fenestrations. Around gestation week 12, fenestrations appear initially with diaphragms. These diaphragms disappear during development [15,170,171].

oxygenated arterial blood mixed with the portal blood derived from the gut and the pancreas containing nutrients, bile acids, and hormones including insulin and glucagon. On the abluminal side, they interact with hepatic stellate cells and hepatocytes that are crucial for protein, lipid and glucose metabolism. LSECs thus represent a permeable barrier allowing exchanges but also active uptake and degradation of molecules [35].

Fluid exchange through fenestrae

Like endothelial cells located in other exchange territories, such as the glomeruli, the spleen and the bone marrow, LSECs are highly permeable [36]. The association of fenestrae, absence of diaphragm and lack of basement membrane make them the most permeable endothelial cells of the mammalian body [24]. These fenestrae are organized in clusters termed sieve plates [37]. LSEC fenestrae have a diameter ranging from 50 to 150 nm [2,37,38]. Their size and number varies depending on their localization in the liver, with larger but fewer fenestrae per sieve plate in the periportal region and smaller but more numerous fenestrae per sieve plate in the centrilobular region [37,39].

This distribution could be related to the progressive decrease in oxygen tension along the lobule accompanied with an increasing need for oxygen exchange [36]. Alternatively, this distribution could be a marker of LSEC maturation as they spread along the lobule [39]. Fenestrae are not static structures. Their number and size varies in physiological conditions like fasting that decreases the number but increases the size of the fenestrae [40] and in pathological conditions [36,39,41–43]. Using super-resolution optical microscopy, Mönkemöller and colleagues recently showed that sieve plates are surrounded and separated by microtubuli and that each fenestra within a sieve plate is surrounded by actin filaments [38]. Cytoskeleton is thus of great importance for the LSEC fenestrations. Fifteen years ago, LSEC fenestrations were thought to be sort of caveolae [44]. Caveolae are uncoated plasma membrane invaginations found in lipid-ordered domains of cell membranes called lipid rafts. Caveolin is a major structural protein of caveolae. Although caveolin-1 has been observed in LSEC fenestrations [44], *caveolin-1* knockout mice have normal fenestrations [45]. In addition, Svistounov and colleagues [46,47] described the “sieve-raft crosstalk”, where fenestrations are formed in reduced lipid-raft regions of endothelial cells. Thus, fenestrations are not dependent on caveolin-1 and are different structures from caveolae.

In a normal liver, LSECs retain blood cells in the vessels, while molecules, such as metabolites, plasma proteins, pharmaceutical drugs, lipoproteins and small chylomicron remnants, viruses (<200 nm) and exosomes can access the space of Disse to be taken up by hepatocytes and hepatic stellate cells [2,38,48]. There is no significant osmotic and hydrostatic pressure gradient across the normal liver sinusoids [41,49]. Small molecules and gasses freely diffuse through the fenestrae, so that the space of Disse contains a para-vascular part of the plasma volume. In addition, as blood cells squeeze into the sinusoids, they massage the endothelial cells and further mix plasma and space of Disse fluids [49]. Larger molecules, may also cross LSEC by a process called permselectivity or “sieving”, namely the restricted transport of large molecules due to their deformation capacity through membrane pores [41]. The fluid present in the space of Disse is drained into hepatic lymphatics, then into hepatic hilum lymphatics, cisterna chيلي, thoracic duct and eventually the central venous circulation, successively [50]. The fluid formed in excess gains free access to the Glisson’s capsule on the liver surface [49]. Contrary to the mesentery, the liver is thus leaky to large molecules including proteins. This explains why ascites related to post-sinusoidal obstruction, such as cardiac failure or Budd-Chiari syndrome, is protein rich while ascites resulting from cirrhosis is not [50].

Key point

LSECs act as a selective barrier, since exchanges occur through fenestrae as well as by transcytosis and LSEC scavenging functions.




Fig. 2. Role of liver sinusoidal cells (LSECs) in chronic liver diseases. In normal conditions, LSECs maintain hepatic stellate cell quiescence through a NO-dependent pathway as long as they are differentiated [101]. Exposure of LSECs to a physiological shear stress activates the transcription factor KLF2 leading to the release of vasodilating agents including nitric oxide (NO) and to the downregulation of vasoconstrictive molecules including endothelin-1. In a cirrhotic liver, LSECs become capillarized, meaning that they lose their fenestrae and a basement membrane appears. Capillarized LSECs permit hepatic stellate cell activation and thus production of collagen and of fibrosis. This change is associated with an endothelial dysfunction meaning that increased shear stress no longer leads to vasodilation but rather to vasoconstriction and thus to increased intrahepatic resistance. Simvastatin restores the vasoprotective effect of KLF2 and improves HSC phenotype through a NO-dependent pathway (the effect of simvastatin appears in red) [102]. BM, basement membrane; E, endothelin; HSC, hepatic stellate cell; KLF2, Kruppel-like factor 2; LSEC, liver sinusoidal cell; NO, nitric oxide.

Endocytic capacity

LSECs have one of the highest endocytic capacity in the human body [51]. This property combined with a strong lysosomal activity give LSECs the ability to clear waste from the blood, as part of the “dual-cell principle” of waste clearance. This principle states that the mononuclear system represents the professional phagocyte, eliminating large particles, and that the scavenger endothelial cells, including LSECs, represents the professional pinocyte, clearing soluble macromolecules and small particles through endocytic receptors [52]. This property can be used to specifically target LSECs. LSEC endocytosis also contributes to the transfer of molecules from the sinusoids to the space of Disse, a process called transcytosis [35]. Endocytosis by LSECs implies different high affinity endocytosis receptors, including scavenger receptors (SR-A, SR-B and SR-H), mannose receptor and Fc gamma-receptor IIb2 [51,52]. The SRs mediate endocytosis of polyanionic molecules, such as oxidized and acetylate low-density lipoproteins (oxLDL and

acLDL), advanced glycation end products and waste products (hyaluronan, chondroitin sulfate or N-terminal propeptides of procollagen (I, III)). The main SRs of LSECs are SR-H/stabilin-1 and SR-H/stabilin-2. *Stabilin1/2* double-knockout mice show only a mild liver fibrosis without liver dysfunction but a severe renal glomerular fibrosis [53], suggesting that stabilin-1 and 2 are major liver endocytic receptors implicated in the clearance of molecules toxic mainly for the kidney. The mannose receptors are not specific of LSECs and bind a wide range of glycoproteins and microbial glycans, such as collagen alpha chains (I, II, III, IV, V, XI), tissue plasminogen activator regulating fibrinolytic activity, and lysosomal enzymes that are recruited for further use in LSEC [54]. Thus, they have a role both in immunity and in glycoprotein homeostasis [52]. The Fc gamma-receptor IIb2 is the only Fc gamma-receptor expressed by LSECs and mediates the clearance of small circulating immune complexes; LSEC play a role in vascular immunity through this receptor [51,52].

Technical aspects for the study of LSECs

Markers of LSEC

Key point

There is no unique specific marker of LSECs, apart from their fenestrae devoid of diaphragm in the absence of basement membrane. A combination of markers is thus mandatory for their identification.

Key point

When cultured, primary LSECs rapidly lose their specific phenotype. However, human and murine immortalized LSECs lines have been successfully developed.

Identification and isolation of LSECs is a major challenge for the understanding of liver physiology and diseases. However, technical barriers as well as a lack of consensual specific LSEC markers explain that LSECs populations differ between research groups, which limits the interpretation and the comparison of the results.

Features used to identify LSECs include: (a) their high and rapid endocytic capacity, using labeled formaldehyde-treated serum albumin, collagen alpha chains or acLDL. As other cells, including Kupffer cells, also have endocytic capacities, labeled molecules have to be incubated in small amount and for a short period of time to be specific for LSECs [55]. (b) Fenestrae without diaphragm and organized in sieve plates, using electron microscopy. Although this feature is the only one specific of LSECs, it has some limitations. First, the distribution of the fenestration varies along the lobule [37]. Second, LSEC isolation methods, including liver perfusion and cell preparation for electron microscopy, dilate fenestrae and might even create holes in cell surface [55]. Third, fenestrae rapidly disappear when LSEC are cultured as a monolayer of cells, out of their environment [56]. This loss of fenestration associated with basement membrane synthesis and modification of the expression of surface markers is called capillarization. Capillarization not only happens in cultured LSEC but also *in vivo* in most liver diseases [56]. (c) surface markers [24] (Table 1). Some markers are common to other endothelial cells and some to hematopoietic cells. No single marker is specific for LSECs and a combination is required. For instance, Ding and colleagues considered that LSEC are VEGFR3⁺ CD34⁺ VEGFR2⁺ VE-Cadherin⁺ FactorVIII⁺ CD45⁺ [57], while Lalor and colleagues selected CD31⁺, LYVE-1⁺, L-SIGN⁺, Stabilin-1⁺, CD34⁺, PROX-1⁺ cells [56]. CD31, CD45 and CD33 deserve specific comments. CD31 (PECAM-1) is an intercellular adhesion molecule classically expressed at the surface of endothelial cells, but also of several leukocytes [58]. The expression of CD31 by LSECs is controversial. Several studies reported CD31 positivity of LSECs in liver slices analyzed by immunohistochemistry or in cultured cells permeabilized before staining [55]. Conversely, for the isolation of LSECs using flow cytometry, LSECs are considered as CD31 negative, CD31 positive cells being arterial and venous endothelial cells as well as capillarized LSECs. An electron microscopic analysis reconciled these results by showing that CD31 is located intracellularly shortly after establishing LSEC cultures, but, when fenestrae disappear few days later, CD31 becomes expressed at the cell surface like in other endothelial cells [59]. CD45 is a hematopoietic cell marker, expressed by leuco-

cytes. LSECs are usually described as CD45⁺, and liver CD45⁺ cells are often considered as Kupffer cells. However, the reality may be more complex, as LSEC CD45 positivity appears to depend on the localization and the differentiation of LSECs [24,39]: bright CD45 positivity is found in periportal area where LSECs have less fenestration, while CD45 negativity appears to predominate in centrilobular areas where LSECs are more differentiated with more fenestrae.

Knowledge of LSEC markers helps understanding some drug adverse effects. For instance, Mylotarg[®] (gemtuzumab ozogamicin), a drug used for acute myeloid leukemia, consists of a humanized antibody anti-CD33, linked to a potent antitumor antibiotic (calicheamicin). CD33 is expressed on the surface of acute myeloid leukemia cells, but also of LSECs likely explaining the high prevalence of hepatic sinusoidal obstruction syndrome following this treatment [60].

LSECs culture

As mentioned above, obtaining a pure culture of primary LSECs is challenging because of the lack of specific markers of these cells. LSEC isolation protocols are detailed elsewhere [61,62]. The culture of LSECs has at least four particularities. First, cultured LSEC tend to lose their typical phenotype. In order to prevent this dedifferentiation, several methods have been developed. Co-culture with hepatocytes and fibroblasts rather than with hepatocytes alone allows LSECs to maintain their phenotype for up to 2 weeks [63]. Extracellular matrix coating mimicking the space of Disse and its modifications in pathology can also be used, e.g., low-density basement membrane-like matrix imitating normal conditions, and interstitial type matrix (fibril-forming collagen) imitating cirrhosis [63]. The addition of VEGF to the medium or the use of hepatocyte-conditioned medium can also prevent LSECs dedifferentiation [56,64,65]. Second, when cultured alone, LSECs undergo apoptosis within 2 days [63]; methods preventing dedifferentiation also prevent cell death. Third, serum supplementation is toxic for LSECs [55]. Fourth, in the normal liver, LSECs are exposed to an oxygen pressure decreasing along the liver lobule from 90 to 30 mmHg [66]; oxygen level is thus lower than in atmospheric conditions where oxygen pressure is 160 mmHg; actually, LSEC are particularly sensitive to hyperoxia and to the resulting oxidative stress [67]; survival of primary LSECs is improved under 5% oxygen instead of the commonly used 20% [51,66].

To overcome the difficulties of culturing primary LSECs, several teams have developed human and murine immortalized LSECs lines. However, the first immortalized lines, obtained by viral transfection such as M1LEC, had no fenestrae [68–72]. Subsequently, several humans and murine immortalized LSEC lines have been developed. As summarized in

Table 1. Liver sinusoidal endothelial cell markers.

| Common with EC markers | Endocytic markers | Antigen presentation | Common with leucocytes | Common with lymphatic EC |
|--------------------------------|---|---------------------------|------------------------|--------------------------|
| CD34 ^s | CD36 | CD40 ^s | CD4 | VAP-1 |
| CD105* | DC-SIGN | CD80 ^s | CD11b | |
| CD146 | L-SIGN | CD86 ^s | CD11c ^s | |
| Cytoplasmic CD31 | Lectins | Fc Gamma R (CD32b**) | CD33 | |
| ICAM-1 | LYVE-1 | Mannose R | CD45 ^s | |
| Ulex Lectin binding | SR-A/SR-B | MHC I/MHC II ^s | Cytoplasmic CD31 | |
| vWf (Factor VIII) ^s | Stabilin-1 | | | |
| | Stabilin-2 | | | |
| | Uptake of acLDL or denatured alpha-collagen chain | | | |

*Also expressed by hepatic stellate cells and myofibroblasts; **correlates with fenestration and corresponds to SE-1 in rats [63]; ^scontroversial [55].

acLDL, acetylated low-density lipoprotein; Ag, antigen; CD, cluster of differentiation; DC-SIGN, dendritic cell-specific intercellular adhesion molecule-3 grabbing non-integrin; EC, endothelial cells; ICAM, intracellular adhesion molecule; L-SIGN, liver specific intercellular adhesion molecule-3 grabbing non-integrin; LDL, low-density lipoprotein; LYVE, lymphatic vessel endothelial hyaluronan acid receptor; MHC, major histocompatibility complex; R, receptor; SR, scavenger receptors; VAP, vascular adhesion protein-1; vWF, von Willebrand factor.

Table 2. Liver sinusoidal endothelial cell lines features.

| Authors | Human lines | | | | Rodent lines | | |
|---------------------------------|--|--|-------------------------------|---|--------------------------|---|----------------------------|
| | Parent <i>et al.</i> [145] | Cogger <i>et al.</i> [146] | Matsumura <i>et al.</i> [68] | Hering <i>et al.</i> [69] | Zhao <i>et al.</i> [147] | Huebert <i>et al.</i> [148] | Maru <i>et al.</i> [70] |
| Name | TRP3 | SK Hep1 | TMNK-1 | iSEC | n.a. | TSEC | NP11, NP26, NP31, and NP32 |
| Origin | Hereditary hemorrhagic telangiectasia patient | Ascitic fluid from a patient with hepatocellular carcinoma | Human liver endothelial cells | Human fetal liver | Mouse | Mouse | Rat |
| Method of immortalization | Lentivirus (hTERT) | Spontaneous | Lentivirus (SV40 and hTERT) | Transfection with polyoma virus large tumor antigen | Spontaneous | Lentivirus (SV40) | Lentivirus (SV40) |
| Fenestration organized in sieve | Few (data not shown) | Yes | n.a. | n.a. | Yes | Few | n.a. |
| CD31 | n.a. | Not at the surface | Yes (RNA) | n.a. | Yes surf. | Yes surf. and cytop. | n.a. |
| Uptake of acLDL | Yes | Yes (uptake of FITC-FSA) | Yes | n.a. | Yes | Yes | Yes |
| Tube forming | Yes | Yes | Yes | Incomplete | Yes | Yes | Only in NP11 and NP26 |
| vWf | Yes perm. | Yes surf. | Yes (RNA) | Yes cytop. | Yes perm. | Yes surf. and cytop. | No |
| CD34 | Yes perm. | n.a. | Yes (RNA) | n.a. | n.a. | n.a. | n.a. |
| Other | CD32b, Stabilin-2, LYVE-1 and cytoplasmic L-SIGN | NOS, VEGFR2 | | Collagen IV, fibronectine | | Chemotaxis in response to angiogenic growth factors | VEGFR-1 (low level) |

acLDL, acetylate low-density lipoproteins; Cytop., cytoplasmic; L-SIGN, liver specific intercellular adhesion molecule-3 grabbing non-integrin; LYVE, lymphatic vessel endothelial hyaluronan acid receptor; FITC, fluorescein isothiocyanate; FSA, formaldehyde-treated serum albumin; n.a., not available; Perm., Permeabilized; Surf., Surface; Spont., Spontaneous; VEGFR, vascular endothelial growth factor receptor; vWf, Von Willebrand factor.

Table 2, these cell lines display many characteristics of LSEC. Each cell line has particular advantages making it more appropriate for specific studies. For instance, TSECs are adequate for angiogenesis analyses and Sk Hep1 for fenestration. However, the fact that these cell lines are immortalized implies that they may react differently from primary cells in response to stress. Therefore, a confirmation of the findings using primary cells is useful.

Mouse models

Transgenic mice using the Cre/Lox system can be very useful to study the properties of LSECs *in vivo*. Briefly, Cre-recombinase, which can be regulated by a tissue-specific promoter, excises essential loxP-flanked ("floxed") genes via intrachromosomal recombination to generate so called conditional knockouts, i.e., knockouts specifically affecting

Table 3. Characteristics of transgenic mice available to study the properties of liver endothelial cells *in vivo*.

| Transgenic mice [Ref.] | Constitutive/ inducible | Liver endothelial expression in adults | | | Expression by hematopoietic cells in adults | Limitation |
|---------------------------------|----------------------------|--|-----------|------------------------|--|--|
| | | Portal vein | Sinusoids | Centri lobular vein | | |
| <i>PECAM1</i> -Cre [149] | Constitutive | n.a. | n.a. | n.a. | Likely | Poorly described |
| <i>Tie1</i> -Cre [150] | Constitutive | n.a. | Good | Good | Yes (20%) | Hematopoietic cell expression |
| <i>Tie2</i> -Cre [151] | Constitutive | Good | Good | Good | Yes (90%) | Strong hematopoietic cell expression |
| <i>Flk1</i> -Cre [17,152] | Constitutive | n.a. | Moderate | n.a. | Yes | Hematopoietic cell expression |
| <i>Cdh5</i> -Cre [12,14] | Constitutive | Good | Good | Good | Yes (50%) | Moderate hematopoietic cell expression |
| <i>Tie2</i> -CreERT2 [153] | Inducible | Good | Absent | n.a. | No | No expression in LSEC |
| Endothelial-SCL-CreERT2 [154] | Inducible | Good | Absent | Absent | No | No expression in LSEC |
| <i>Cdh5</i> -CreERT2 [155] | Inducible | n.a. | Mild | Mild | No | Less penetrant than <i>Cdh5</i> (PAC)-CreERT2 |
| <i>Cdh5</i> (PAC)-CreERT2 [156] | Inducible | Good | Good | Good | No | |
| <i>Pdgfrb</i> -iCreERT2 [157] | Inducible | n.a. | Absent | Good | No during the first month after induction of Cre- mediated recombination | No expression in LSEC |
| <i>Bmx cre</i> [158] | Constitutive | Absent | Absent | Absent | n.a. | Artery specific |

Recombination was classified as good (>66%), moderate (33–66%), mild (5–33%); absent (<5%) based on data provided in the articles describing each model for all mouse lines but *Tie2*-Cre, *Pdgfrb*-iCreERT2 and *Cdh5* (PAC)-CreERT2. Indeed, these last 3 lines were independently and thoroughly analyzed and compared back to back using mT/mG reporter mice by the group of C James, Pessac, France (Kilani *et al.*, unpublished). *Cdh5*-CreERT2 mice were also analyzed using mT/mG reporter by our group (unpublished data). Regarding LSEC expression, caution is needed since in all cases LacZ staining was performed without immunohistochemistry. Cells considered as LSEC were thus sinusoidal cells. They may be LSEC but also may be Kupffer cells. LSEC, liver sinusoidal endothelial cell; n.a., information not available.

Key point

The loss of the specific phenotype of LSECs, including the disappearance of the fenestrae, the development of a basement membrane, and the appearance of specific markers is called capillarization and is an early event in chronic liver injury. When capillarized, LSECs lose their capacity to inactivate hepatic stellate cells, thus promoting fibrogenesis and intrahepatic vasoconstriction.

tissues where the promoter is expressed. Several models with an endothelial cell expression of the Cre-recombinase have been developed and are summarized in Table 3. Mice with a constitutive expression of the Cre-recombinase appeared first. However, the expression of the Cre-recombinase is not restricted to endothelial cells, especially in adult mice, as recombination also occurs in hematopoietic cells. Indeed, early embryonic endothelial and hematopoietic cells arise from a common embryonic precursor called the hemangioblast [14]. This limitation can be overcome by performing a transplantation of wild-type bone marrow together with a clodronate mediated Kupffer cell depletion [73]. Indeed, in the absence of clodronate treatment, 2 months after bone marrow transplantation, 85% of the Kupffer cells are still derived from the recipient [74]. Myeloablation conditionings required for bone marrow transplantation might however alter LSEC function. Another way to overcome the concomitant expression of the Cre-recombinase in endothelial and hematopoietic cells is to use transgenic lines where Cre expression is induced in adult endothelial cells after tamoxifen administration. In that case, there is no expression of the transgene in hematopoietic cells.

LSECs in liver diseases

Chronic liver diseases

LSECs play a key role in chronic liver disease initiation and progression, through four processes:

sinusoid capillarization, angiogenesis, angiocrine signals and vasoconstriction.

Capillarization of LSECs, also called dedifferentiation, occurs following liver injury in animal models as well as in patients [75–80]. Capillarization is an early event since it precedes the activation of hepatic stellate cells and macrophages and the onset of liver fibrosis, suggesting that it could be a preliminary step necessary for fibrogenesis [76,81,82]. The mechanisms of capillarization and the cross talk between LSECs and hepatic stellate cells has been reviewed elsewhere [83]. Briefly, LSECs are able to maintain hepatic stellate cells quiescent as long as they are differentiated so that differentiated LSECs are gatekeepers of fibrosis [34,84]. VEGF contributes to the maintenance of LSEC differentiation (Fig. 3). The role of LSECs in fibrosis regression is less clear. Indeed, in experimental models, restoration of LSEC differentiation *in vivo* promotes regression of mild fibrosis [34,85]. However, immunohistochemical analysis of paired liver biopsies from 38 hepatitis C virus patients with cirrhosis, before and after antiviral treatment, revealed that sinusoid capillarization persists despite the regression of cirrhosis. LSEC differentiation is thus not crucial for fibrosis regression in this setting [86].

Angiogenesis is defined by the development of new vessels from preexistent vessels [87]. Hepatic angiogenesis occurs during liver fibrogenesis and these two processes are closely linked [88,89]. Liver fibrosis enhances angiogenesis and, in turn, liver angiogenesis aggravates liver fibrosis, as attested by the anti-fibrotic effect of most anti-angiogenic




Fig. 3. A dual role of VEGF in chronic liver disease progression. In physiological conditions, VEGF released by hepatocytes, cholangiocytes and HSC, maintains LSEC differentiation (blue arrow) and consequently HSC quiescence. VEGF is thus anti-fibrogenic. During fibrogenesis, liver expression of VEGF increases. These high VEGF levels have a pro-fibrogenic action (red arrows) by inducing liver angiogenesis and by activating HSC. The activation of HSC results from a direct action of VEGF on HSC and from the release of TGF-β1 by capillarized LSECs. BM, basement membrane; HSC, hepatic stellate cell; LSEC, liver sinusoidal cell; VEGF, vascular growth factor; TGF-β1, transforming growth factor β1.

agents in animal models of liver fibrosis [90,91]. However, analysis of the relationships between angiogenesis and fibrogenesis is not straightforward since most tools used to inhibit angiogenesis also act on fibrogenesis. For instance, VEGF, the master regulator of angiogenesis, is also implicated in fibrogenesis (Fig. 3) [87,92–95]. Besides LSECs, endothelial progenitor cell (EPC), i.e., endothelial cells derived from bone marrow, also contribute to liver angiogenesis, as reviewed elsewhere [96,97].

LSECs also regulate fibrosis by releasing angiocrine signals. This latter term refers to the paracrine factors produced by endothelial cells that maintain organ homeostasis, balance the self-renewal and differentiation of stem cells and orchestrate organ regeneration and tumor growth. A recent landmark study demonstrated that LSECs release divergent angiocrine signals balancing liver regeneration and fibrosis. After acute liver injury, activation of CXCR7-Id1 pathway in LSECs stimulates production of hepatic-active angiocrine factors leading to liver regeneration. By contrast, chronic injury causes persistent FGFR1 activation in LSECs that perturbs CXCR7-Id1 pathway and favors a CXCR4-driven pro-fibrotic angiocrine response, thereby provoking liver fibrosis. Therefore, in response to injury, differentially primed LSECs deploy divergent angiocrine signals to balance liver regeneration and fibrosis [98].

Endothelial dysfunction occurs early in chronic liver disease, even before fibrosis and inflammation take place, and persists in advanced cirrhosis [84,99,100] (Fig. 2). The mechanisms of endothelial dysfunction have been reviewed elsewhere and are summarized in Fig. 2 [83,84]. Importantly, pharmacologic strategies improving LSECs in chronic liver diseases, including statins, decrease liver fibrosis, endothelial dysfunction and portal pressure [101,103,104].

Role of LSECs in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) most often emerges in the context of chronic liver disease. The development of HCC is thought to be a multistep process from precancerous lesions (low then high grade dysplastic nodule) to early and advanced HCC [105]. Dysplastic nodules receive blood supply preferentially via the portal vein similarly to regenerative nodules of cirrhosis. A switch to prominent arterial blood supply occurs at the stage of early HCC [106]. Then, angiogenesis results in a highly vascularized tumor and promotes tumorigenesis and the development of metastasis. HCC is associated with changes in endothelial cells within and around the tumor.

Endothelial cells present within HCC sequentially lose during tumor progression LSECs markers, including stabilin-1, stabilin-2, LYVE-1 and CD32b,

as observed both in murine HCC models and in human HCC [107]. Moreover, as compared to LSECs from a healthy human liver, endothelial cells derived from human HCC have a higher expression of integrins, lower expression of ICAM-1, and exhibit higher angiogenic, procoagulant and fibrinolytic capacities [108].

LSECs in the peritumoral tissue also undergo changes as HCC progresses including the loss of the LSEC markers stabilin-2 and CD32b [107]. In a mouse tumor xenograft model, peritumoral liver tissue displays a higher microvascular density and expression of the proangiogenic genes, interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) than the model tumoral tissue [109]. In the same line, peritumoral endothelial cells isolated from patients with HCC proliferate more when cultured with IL-6 and soluble IL-6R than tumoral endothelial cells. IL-6 is secreted by peritumoral endothelial cells in response to hypoxia while IL-6R is secreted by macrophages, present in large number in the peritumoral liver tissue during tumoral progression. These data suggesting a major role of peritumoral endothelial cells in HCC progression echo the previous observation that gene expression in the nontumoral liver from patients with HCC has a higher prognostic value of than gene expression in HCC [110].

LSEC and liver regeneration following acute liver injury or partial hepatectomy

Liver regeneration following acute liver injury or partial hepatectomy is a complex process where LSECs play a key role. LSECs sense the major changes in shear stress resulting from resection. They proliferate, and orchestrate the harmonious regeneration of the different cell types by interacting with sinusoidal progenitor cells, platelets and inflammatory cells (Fig. 4).

After an acute liver injury or a partial hepatectomy, LSECs play a central role in liver regeneration through a dynamic regulation of the balance between hepatocytes proliferation and vascular proliferation. There is an asynchronism between hepatocyte and LSEC proliferation. In the early phase (at day 2), non-proliferative LSECs activate hepatocytes proliferation by two complementary mechanisms: (a) the downregulation of the hepatocyte growth inhibitor TGF- β , through the downregulation of the Tie2 receptor antagonist, angiopoietin-2 [111]; and (b) the secretion of hepatotropic cytokines, Wnt and hepatocyte growth factor (HGF), through the upregulation of the transcription factor Id1 via the VEGFR2/VEGFA pathways [57]. Following liver resection, the portal flow per gram of tissue immediately increases, enhancing the shear stress on LSECs [112,113]. In response to this increased shear stress, LSECs release NO that sensitizes hepatocytes to HGF

[112,114]. Shear stress is thus a key inducer of liver regeneration. However, when resection is excessive, exaggerated shear stress can damage LSECs and lead to hemorrhagic necrosis [112]. Limiting shear stress could be a potential strategy to prevent post-hepatectomy liver failure as suggested by the beneficial effect of portosystemic shunts, splenectomy or splenic artery embolization in murine models and in patients with large liver resections [112,115–121]. A less invasive surgical intervention is being tested in a prospective trial (NCT02390713), using a pneumatic ring to modulate the diameter of the portal vein and thus the post-hepatectomy shear stress. New promising molecules decreasing shear stress to prevent post-hepatectomy liver failure and small-for-size-syndrome have been proposed including the vasodilator olprinone, a phosphodiesterase III inhibitor [122,123] currently tested in a prospective trial (NCT00966745).

In the second phase following hepatectomy (at day 4), LSECs begin to proliferate, via the upregulation of angiopoietin-2 and VEGFR2/VEGFA pathways [111]. VEGFR2 is a classical mediator of the mitogenic and the angiogenic effect of VEGFA. The role of VEGFA/VEGFR1 pathway is more controversial than that of the VEGFR2 pathway. Le Couteur *et al.* described that VEGFR1 activation in LSECs after liver injury, can paracrinally induce hepatocyte proliferation, without LSEC proliferation and protects parenchymal cells from the injury [124].

Liver regeneration not only implicates liver cells but also circulating cells including sinusoidal progenitor cells, platelets and inflammatory cells. The role of sinusoidal progenitor cells in liver regeneration has been recently reviewed elsewhere and is summarized in Fig. 4 [20]. Briefly, liver injury induces increased hepatic VEGF expression, which drives recruitment of hepatocyte growth factor-rich bone marrow sinusoidal progenitor cells and promotes expression of HGF by resident sinusoidal progenitor cells and LSECs. HGF in turn stimulates the proliferation of hepatocytes in liver regeneration. In addition, sinusoidal progenitor cells replace LSECs that were lost during injury. The role of the interaction between LSECs and platelets in liver regeneration is summarized in Fig. 4 [125]. Following liver injury, platelets are recruited to and trapped within the liver, where they adhere to LSEC. Subsequent platelet activation results in the release of platelet granules, which stimulate hepatocyte proliferation. Platelets activate LSECs, leading to the secretion of growth factors, such as IL-6 [125]. Finally, LSECs and hepatocytes can also internalize platelets, but the effects of this alternate process on liver regeneration remain to be explored. The improvement in survival following subtotal liver resection in rats and mice obtained by the induction of thrombocytosis by thrombopoietin injection, splenectomy or platelet-rich plasma transfusion illustrates importance of platelets in liver regeneration [126–128]. The endothelial-monocyte interac-

Key point

LSECs are implicated in liver regeneration following acute liver injury or partial hepatectomy since they renew from LSECs and/or LSEC progenitors, they sense the shear stress changes resulting from surgery and interact with platelets and inflammatory cells.




Fig. 4. Liver sinusoidal cell (LSECs) and liver regeneration following acute liver injury or partial hepatectomy. Following liver injury, liver expression of VEGF increases, leading to the proliferation of bone marrow sinusoidal progenitor cells (SPC) (1), to their mobilization to the circulation (2), their engraftment in the sinusoids (3) and their differentiation in mature LSECs (4). VEGF A stimulates liver regeneration through LSECs (a) leading to HGF production (b), hepatocyte proliferation (c) and LSECs proliferation (d) [20]. Increased shear stress associated with liver resection induces LSECs derived nitric oxide (NO) (I), which increase the effect of HGF on hepatocytes proliferation (II). Platelets are rapidly recruited in the liver after liver surgery (A). They adhere to LSECs and stimulate secretion of key molecules involved in hepatocytes (F) and LSECs (B) proliferation and survival. Platelets can also be endocytosed by LSECs (C), or trapped in the space of Disse (E), a migration facilitated by the increased size of fenestration associated with liver surgery (D). Abbreviations: HSC, hepatic stellate cell; NO, nitric oxide; LSEC, liver sinusoidal cell; HGF, hepatocyte growth factor; VEGF, vascular growth factor; VEGFR, vascular growth factor receptor; SPC, sinusoid progenitor cells.

tion is also implicated in liver regeneration. Indeed, circulating monocytes are recruited in the injured liver and stimulate parenchymal but also endothelial regeneration. LSECs regulate the infiltration of monocyte in the liver through a destabilization of VE-Cadherin junction and through adhesive molecule expression [129].

Lastly, liver regeneration also depends on the existence of lesion related to ischemia reperfusion. Mechanisms of ischemia reperfusion injury have been reviewed previously and will not be detailed here [130].

Inflammation and infection

LSECs regulate liver inflammation in two manners. First, LSECs are a barrier separating the blood from the rest of liver, and thus restrict or enable the entry of circulating leucocytes into the liver tissue. The detailed mechanisms of the interactions between leucocytes and LSECs have been previously reviewed [131]. Briefly, LSECs express ICAM-1 and vascular adhesion protein-1 (VAP-1), allowing adhesion of leucocytes to the endothelium. During inflammation, expression of ICAM-1

increases and expression of vascular cell adhesion molecule-1 (VCAM-1) and CD31 are induced, leading to the transendothelial migration of leucocytes. Stabilin-1 has also been reported to promote transendothelial migration of leucocytes, preferentially regulatory T cells [132]. Second, LSECs can modulate lymphocytes behavior. In physiological conditions, antigen presentation by LSECs leads to tolerance induction in CD8⁺ cells [133]. LSECs can also induce differentiation of T cells into immunosuppressive regulatory T cells (Treg) that are functional *in vitro* and *in vivo* [134]. As an application, the selective delivery of autoantigen peptides to LSECs *in vivo* using a polymeric nanoparticle carrier can efficiently prevent and treat an animal model of autoimmunity, by increasing the number of Treg [135]. In inflammatory conditions, LSECs also tend to have an anti-inflammatory action since they increase the expression of the anti-inflammatory cytokine IL-10 in Th1 cells via the Notch pathway [136].

But LSECs can also be targeted by pathogens. Due to their scavenging ability, LSECs can capture circulating viruses via the expression of lectin at their surface and in turn induce infection of hepatocytes,

Table 4. Drug delivery system to LSEC *in vivo*.

| Reference | Carrier | Size (nm) | Carrier distribution <i>in vivo</i> | | | | Experimental strategies and results | Toxicity |
|------------------------------|------------------------------------|------------|-------------------------------------|----------|------------|---|---|------------------------------|
| | | | LSEC* | KC* | Hep* | Other organs | | |
| Sano <i>et al.</i> [159] | HA | n.a. | Yes | n.a. | n.a. | n.a. | Delivering of sphingosine-1-phosphate Hepatic I/R injury model in rats →↓ALT level and hepatocytes and LSECs apoptosis | n.a. |
| Fraser <i>et al.</i> [160] | HA | n.a. | 90% | 0 | 4% | Low in spleen | Bio-distribution in rats | n.a. |
| Toriyabe <i>et al.</i> [161] | HA-SA-liposome | 254 ± 19 | Yes | Yes (NQ) | No (NQ) | Low expression in lungs | Bio-distribution in mice | n.a. |
| Takei <i>et al.</i> [162] | PLL-g-HA | 100 to 200 | Yes | No (NQ) | No (NQ) | >93% liver 2.5-1% spleen, intestine and kidney <1% heart, thymus, lung and blood [§] | Delivering of DNA complexes Bio-distribution in rats | n.a. |
| Kren <i>et al.</i> [163] | HA-nanocapsule (polyethyleneimine) | <50 | Yes | n.a. | No (NQ) | Not in lung, kidney, spleen, heart and gonads | Delivering of transposon vectors expressing FVIII Hemophilia A mice model →Normalization of plasmatic FVIII expression and activity up to 11 mo | No toxicity in 72 h and 3 mo |
| Carambia <i>et al.</i> [135] | Iron oxide nanocrystals | <50 | Yes | n.a. | No (NQ) | 90% liver 10% spleen and kidney [§] | Delivering of auto-antigen peptide Autoimmune encephalomyelitis mice model →Controlled disease progression by Treg induction by LSECs | No toxicity (9 wk) |
| Tanoi <i>et al.</i> [164] | STR-KLGR modified YSK05-MEND | 80-120 | Yes | n.a. | Lower (NQ) | n.a. | Delivering of BAX siRNA Acute liver damage (anti-FAS Ab) in mice →↓Hepatocytes apoptosis. Preserve sinusoidal structure | 100% alive at 24 h |
| Akhter <i>et al.</i> [165] | STR-KLGR modified YSK05-MEND | 80-120 | Yes | n.a. | Low | High in liver Lower expression in lung and kidney | Delivering of Tle2 siRNA Bio-distribution in mice →80% knockdown in LSECs | No liver toxicity (24 h) |
| Bartsch <i>et al.</i> [166] | Aco-HSA-CCLs | 154 ± 12 | 60% | 40% | 1.30% | 60% liver 4% spleen <1% lungs, heart, kidneys [§] | Delivering of ODN Bio-distribution in rats | n.a. |
| Kamps <i>et al.</i> [167] | Aco-HSA liposomes | 92.1 ± 10 | 65% | 25% | 10% | 80% liver 5% spleen [§] | Bio-distribution in rats | n.a. |
| Bartsch <i>et al.</i> [168] | Aco-HSA-PEG-SAPLs | 164 ± 45 | 75% | 25% | n.a. | 80 % liver 5% spleen [§] | Delivering of anti-ICAM-1-ODN No efficiency analyze <i>in vivo</i> | n.a. |

* % of expression in liver cells; [§]Express as % of body distribution; [§]Express as % of injected dose.

Ab, antibody; Aco-HAS, cis-aconitylated human serum albumin; ALT, alanine aminotransferase; CCLs, lipid-coated cationic lipoplexes; Hep, hepatocytes; HA, hyaluronic acid; I/R, ischemia reperfusion; ICAM, intracellular adhesion molecule; KC, Kupffer cells; LSECs, liver sinusoidal endothelial cells; MEND, multifunctional type nano device; n.a., not available; NQ, not quantified; ODN, antisense oligodeoxynucleotides; PEG, polyethylene glycol; PLL-g-HA, hyaluronate-grafted poly(L-lysine) copolymer; SA, stearylamine; SAPLs, stabilized antisense lipid particles; siRNA, small interfering RNA; STR-KLGR, sterylated killer cell lectin-like receptor subfamily G; Treg, regulatory T cells; YSK05, pH-sensitive cationic lipid [169].

as observed for hepatitis B and hepatitis C viruses [137,138]. Lectin expressed by LSECs is not only involved in regulation of the entry of viruses but also in the regulation of their clearance by modulating functions of T cells as it has been shown for adenovirus [139]. LSECs can also be infected with CMV (cytomegalovirus) which upregulates ICAM-1 and CXCL10 expression, thus favoring CD4 T cell transendothelial migration. Migration of effector memory T cells through CMV-infected LSECs is associated with a change in memory T cells phenotype towards an activated phenotype facilitating hepatic inflammation, while regulatory T cells

transmigrating retain a suppressive phenotype, favoring virus persistence [140]. This change in endothelial cells towards a proinflammatory phenotype induced by CMV might explain why acute CMV infection can trigger portal vein thrombosis [141]. The effect of CMV on LSECs and lymphocytes may also be of particular interest in the setting of liver transplantation where CMV infection may favor acute rejection, a disease characterized by endotheliitis.

LSECs can also be infected with bacteria as electron microscopy studies revealed *Bartonella bacilli* in LSECs associated with angiomas and peliosis

hepatitis [142]. The fact that LSECs can be targets for pathogens with an impact on the local environment might explain why nodular regenerative hyperplasia develops in patients with primary hypogammaglobulinemia, a condition frequently associated with intra-sinusoidal lymphocytic infiltration. Immunodeficiency might favor infection of LSECs with pathogens, leading to a change in their phenotype towards a proinflammatory and prothrombotic phenotype and eventually to sinusoid obstruction [143].

LSEC and ageing

Pseudocapillarization refers to changes in the liver sinusoidal endothelium related with ageing. Electron microscopy analyses showed that ageing is associated with a 50% increase in the thickness of LSECs, a 50% reduction in the number of LSEC fenestrae and the formation of a basement membrane with perisinusoidal fibrosis and central vein fibrosis [42,82]. These changes decrease porosity and endocytic capacity of LSECs. Consequently clearance of chylomicron remnants is impaired leading to post prandial triglyceridemia, which could participate to atherosclerosis development in older individuals [42,51]. Moreover, these LSEC changes can induce hepatocytes hypoxemia decreasing oxidative drug metabolism and possibly promoting adverse drug reactions [42,51,144].

Conclusion

In conclusion, LSECs have a unique highly permeable phenotype allowing the passage of certain but not all molecules and cells. They also have a very special localization at the interface between blood cells on the one side and hepatocytes and hepatic stellate cells on the other side. LSECs are in constant interaction with other liver cells [83].

LSECs are implicated in most liver diseases including chronic liver disease initiation and progression, hepatocellular carcinoma development and progression, liver regeneration following acute liver injury or partial hepatectomy, liver ageing and liver lesions related to inflammation and infection. This role in most liver diseases makes them an attractive therapeutic target. Data summarized in Table 4 suggest a promising place to specific LSECs targeting. Such cell-specific approaches may limit the adverse effects associated with systemic drug delivery.

Financial support

This work was supported by the Agence Nationale pour la Recherche (ANR-14-CE12-0011 and ANR-14-CE35-0022) and by the Association Francaise pour l'Etude du foie (AFEF 2014) and J.P by the "poste d'accueil INSERM".

Conflict of interest

The authors declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

Authors' contributions

JP, SL and PER drafted the manuscript. FD, CMB, RM and DV discussed and critically revised the manuscript.

Acknowledgments

We thank Servier medical art for providing some images included in the figures.

References

Author names in bold designate shared co-first authorship

- [1] Chiu J-J, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. *Physiol Rev* 2011;91:327–387.
- [2] Maslak E, Gregorius A, Chlopicki S. Liver sinusoidal endothelial cells (LSECs) function and NAFLD; NO-based therapy targeted to the liver. *Pharmacol Rep* 2015;67:689–694.
- [3] Couvelard A, Scoazec JY, Dauge MC, Bringuier AF, Potet F, Feldmann G. Structural and functional differentiation of sinusoidal endothelial cells during liver organogenesis in humans. *Blood* 1996;87:4568–4580.
- [4] Walter TJ, Cast AE, Huppert KA, Huppert SS. Epithelial VEGF signaling is required in the mouse liver for proper sinusoid endothelial cell identity and hepatocyte zonation in vivo. *Am J Physiol Gastrointest Liver Physiol* 2014;306:G849–G862.
- [5] Takabe Y, Yagi S, Koike T, Shiojiri N. Immunomagnetic exclusion of E-cadherin-positive hepatoblasts in fetal mouse liver cell cultures impairs morphogenesis and gene expression of sinusoidal endothelial cells. *J Anat* 2012;221:229–239.
- [6] Gouysse G, Couvelard A, Frachon S, Bouvier R, Nejari M, Dauge MC, et al. Relationship between vascular development and vascular differentiation during liver organogenesis in humans. *J Hepatol* 2002;37:730–740.
- [7] Shiojiri N, Sugiyama Y. Immunolocalization of extracellular matrix components and integrins during mouse liver development. *Hepatology* 2004;40:346–355.
- [8] Asahina K, Zhou B, Pu WT, Tsukamoto H. Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. *Hepatology* 2011;53:983–995.
- [9] Jaffredo T, Nottingham W, Liddiard K, Bollerot K, Pouget C, de Bruijn M. From hemangioblast to hematopoietic stem cell: an endothelial connection? *Exp Hematol* 2005;33:1029–1040.
- [10] Bollerot K, Pouget C, Jaffredo T. The embryonic origins of hematopoietic stem cells: a tale of hemangioblast and hemogenic endothelium. *APMIS* 2005;113:790–803.
- [11] Bailey AS, Fleming WH. Converging roads: evidence for an adult hemangioblast. *Exp Hematol* 2003;31:987–993.

- [12] Alva JA, Zovein AC, Monvoisin A, Murphy T, Salazar A, Harvey NL, et al. VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. *Dev Dyn* 2006;235:759–767.
- [13] Zovein AC, Hofmann JJ, Lynch M, French WJ, Turlo KA, Yang Y, et al. Fate tracing reveals the endothelial origin of hematopoietic stem cells. *Cell Stem Cell* 2008;3:625–636.
- [14] Oberlin E, El Hafny B, Petit-Cocault L, Souyri M. Definitive human and mouse hematopoiesis originates from the embryonic endothelium: a new class of HSCs based on VE-cadherin expression. *Int J Dev Biol* 2010;54:1165–1173.
- [15] Martinez-Hernandez A, Amenta PS. The hepatic extracellular matrix. II. Ontogenesis, regeneration and cirrhosis. *Virchows Arch* 1993;423:77–84.
- [16] Shiojiri N, Niwa T, Sugiyama Y, Koike T. Preferential expression of connexin37 and connexin40 in the endothelium of the portal veins during mouse liver development. *Cell Tissue Res* 2006;324:547–552.
- [17] Sugiyama Y, Takabe Y, Nakakura T, Tanaka S, Koike T, Shiojiri N. Sinusoid development and morphogenesis may be stimulated by VEGF-Flk-1 signaling during fetal mouse liver development. *Dev Dyn* 2010;239:386–397.
- [18] Zhang H, Pu W, Tian X, Huang X, He L, Liu Q, et al. Genetic lineage tracing identifies endocardial origin of liver vasculature. *Nat Genet* 2016;48:537–543.
- [19] Davies PF, Civelek M, Fang Y, Fleming I. The atherosusceptible endothelium: endothelial phenotypes in complex haemodynamic shear stress regions in vivo. *Cardiovasc Res* 2013;99:315–327.
- [20] DeLeve LD. Liver sinusoidal endothelial cells and liver regeneration. *J Clin Invest* 2013;123:1861–1866.
- [21] Margreet De Leeuw A, Brouwer A, Knook DL. Sinusoidal endothelial cells of the liver: Fine structure and function in relation to age. *J Electron Microscop* 1990;14:218–236.
- [22] Wang L, Wang X, Xie G, Wang L, Hill CK, DeLeve LD. Liver sinusoidal endothelial cell progenitor cells promote liver regeneration in rats. *J Clin Invest* 2012;122:1567–1573.
- [23] Harb R, Xie G, Lutzko C, Guo Y, Wang X, Hill CK, et al. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury. *Gastroenterology* 2009;137:704–712.
- [24] DeLeve LD, Garcia-Tsao G. Vascular liver disease – mechanisms and management. Springer Science+Business media, LLC; 2011. http://dx.doi.org/10.1007/978-1-4419-8327-5_2.
- [25] Lee SS, Hadengue A, Moreau R, Sayegh R, Hillon P, Lebrec D. Postprandial hemodynamic responses in patients with cirrhosis. *Hepatology* 1988;8:647–651.
- [26] Davies PF. Flow-mediated endothelial mechanotransduction. *Physiol Rev* 1995;75:519–560.
- [27] Gracia-Sancho J, Russo L, García-Calderó H, García-Pagán JC, García-Cardeña G, Bosch J. Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. *Gut* 2011;60:517–524.
- [28] Parmar KM, Larman HB, Dai G, Zhang Y, Wang ET, Moorthy SN, et al. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. *J Clin Invest* 2006;116:49–58.
- [29] Shah V, Haddad FG, Garcia-Cardena G, Frangos JA, Mennone A, Groszmann RJ, et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. *J Clin Invest* 1997;100:2923.
- [30] Fernandez M. Molecular pathophysiology of portal hypertension. *Hepatology* 1955;61:1406–1415.
- [31] Kawada N, Tran-Thi T-A, Klein H, Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. *Eur J Biochem* 1993;213:815–823.
- [32] McCuskey RS. Morphological mechanisms for regulating blood flow through hepatic sinusoids. *Liver* 2000;20:3–7.
- [33] Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. *Hepatology* 1997;25:2–5.
- [34] DeLeve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. *Hepatology* 2008;48:920–930.
- [35] Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. *Comp Hepatol* 2002;1:1.
- [36] DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. *Hepatology* 2015;61:1740–1746.
- [37] Wisse E, De Zanger RB, Charels K, Van Der Smitten P, McCuskey RS. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. *Hepatology* 1985;5:683–692.
- [38] Mönkemöller V, Øie C, Hübner W, Huser T, McCourt P. Multimodal super-resolution optical microscopy visualizes the close connection between membrane and the cytoskeleton in liver sinusoidal endothelial cell fenestrations. *Sci Rep* 2015;5:16279.
- [39] Xie G, Wang L, Wang X, Wang L, DeLeve LD. Isolation of periportal, midlobular, and centrilobular rat liver sinusoidal endothelial cells enables study of zonated drug toxicity. *AJP Gastrointest Liver Physiol* 2010;299:G1204–G1210.
- [40] O'Reilly JN, Cogger VC, Fraser R, Le Couteur DG. The effect of feeding and fasting on fenestrations in the liver sinusoidal endothelial cell. *Pathology (Phila)* 2010;42:255–258.
- [41] Fraser R, Cogger VC, Dobbs B, Jamieson H, Warren A, Hilmer SN, et al. The liver sieve and atherosclerosis. *Pathology (Phila)* 2012;44:181–186.
- [42] Le Couteur DG, Fraser R, Cogger VC, McLean AJ. Hepatic pseudocapillarisation and atherosclerosis in ageing. *Lancet* 2002;359:1612–1615.
- [43] Arias IM. The biology of hepatic endothelial cell fenestrae. *Prog Liver Dis* 1990;9:11–26.
- [44] Yokomori H, Oda M, Ogi M, Kamegaya Y, Tsukada N, Ishii H. Endothelial nitric oxide synthase and caveolin-1 are co-localized in sinusoidal endothelial fenestrae. *Liver* 2001;21:198–206.
- [45] Warren A, Cogger VC, Arias IM, McCuskey RS, Le Couteur DG. Liver sinusoidal endothelial fenestrations in caveolin-1 knockout mice. *Microcirculation* 1994;20:32–38.
- [46] Svistounov D, Warren A, McNeerney GP, Owen DM, Zencak D, Zykova SN, et al. The Relationship between fenestrations, sieve plates and rafts in liver sinusoidal endothelial cells. *PLoS One* 2012;7 e46134.
- [47] Rodriguez-Vita J, Morales-Ruiz M. Down the liver sinusoidal endothelial cell (LSEC) hole. Is there a role for lipid rafts in LSEC fenestration? *Hepatology* 2013;57:1272–1274.
- [48] Géraud C, Evdokimov K, Straub BK, Peitsch WK, Demory A, Dörflinger Y, et al. Unique cell type-specific junctional complexes in vascular endothelium of human and rat liver sinusoids. *PLoS One* 2012;7.
- [49] Lauth WW. Hepatic circulation: physiology and pathophysiology. San Rafael, CA: Morgan & Claypool Life Sciences; 2009.
- [50] Rodés J, Benhamou J-P, Blei A, Reichen J, Rizzetto M. Textbook of hepatology: from basic science to clinical practice. 3rd ed. Blackwell Publishing; 2007.
- [51] Smedsrød B, Le Couteur D, Ikejima K, Jaeschke H, Kawada N, Naito M, et al. Hepatic sinusoidal cells in health and disease: update from the 14th International Symposium: Hepatic sinusoidal cells in health and disease. *Liver Int* 2009;29:490–501.
- [52] Sorensen KK, McCourt P, Berg T, Crossley C, Couteur DL, Wake K, et al. The scavenger endothelial cell: a new player in homeostasis and immunity. *Am J Physiol Regul Integr Comp Physiol* 2012;303:R1217–R1230.
- [53] Schledzewski K, Géraud C, Arnold B, Wang S, Gröne H-J, Kempf T, et al. Deficiency of liver sinusoidal scavenger receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired hepatic clearance of noxious blood factors. *J Clin Invest* 2011;121:703–714.
- [54] Elvevold K, Simon-Santamaria J, Hasvold H, McCourt P, Smedsrød B, Sørensen KK. Liver sinusoidal endothelial cells depend on mannose receptor-mediated recruitment of lysosomal enzymes for normal degradation capacity. *Hepatology* 2008;48:2007–2015.
- [55] Elvevold K, Smedsrød B, Martinez I. The liver sinusoidal endothelial cell: a cell type of controversial and confusing identity. *Am J Physiol Gastrointest Liver Physiol* 2008;294:G391–G400.
- [56] Lalor PF, Lai WK, Curbishley SM, Shetty S, Adams DH. Human hepatic sinusoidal endothelial cells can be distinguished by expression of phenotypic markers related to their specialised functions in vivo. *World J Gastroenterol* 2006;12:5429–5439.
- [57] Ding B-S, Nolan DJ, Butler JM, James D, Babazadeh AO, Rosenwaks Z, et al. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. *Nature* 2010;468:310–315.
- [58] Woodfin A, Voisin M-B, Nourshargh S. PECAM-1: a multi-functional molecule in inflammation and vascular biology. *Arterioscler Thromb Vasc Biol* 2007;27:2514–2523.
- [59] DeLeve LD, Wang X, Hu L, McCuskey MK, McCuskey RS. Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. *Am J Physiol Gastrointest Liver Physiol* 2004;287:G757–G763.
- [60] Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). *J Clin Exp Hepatol* 2014;4:332–346.
- [61] Smedsrød B. Protocol for preparation of mouse liver Kupffer cells and liver sinusoidal endothelial cells, 2012.

- [62] Meyer J, Gonelle-Gispert C, Morel P, Bühler L. Methods for isolation and purification of murine liver sinusoidal endothelial cells: a systematic review. *PLoS One* 2016;11:e0151945.
- [63] March S, Hui EE, Underhill GH, Khetani S, Bhatia SN. Microenvironmental regulation of the sinusoidal endothelial cell phenotype in vitro. *Hepatology* 2009;50:920–928.
- [64] Yokomori H, Oda M, Yoshimura K, Nagai T, Ogi M, Nomura M, et al. Vascular endothelial growth factor increases fenestral permeability in hepatic sinusoidal endothelial cells. *Liver Int* 2003;23:467–475.
- [65] Krause P, Markus PM, Schwartz P, Unthan-Fechner K, Pestel S, Fandrey J, et al. Hepatocyte-supported serum-free culture of rat liver sinusoidal endothelial cells. *J Hepatol* 2000;32:718–726.
- [66] Martinez I, Nedredal GI, Øie CI, Warren A, Johansen O, Le Couteur DG, et al. The influence of oxygen tension on the structure and function of isolated liver sinusoidal endothelial cells. *Comp Hepatol* 2008;7:4.
- [67] Motoyama S, Minamiya Y, Saito S, Saito R, Matsuzaki I, Abo S, et al. Hydrogen peroxide derived from hepatocytes induces sinusoidal endothelial cell apoptosis in perfused hypoxic rat liver. *Gastroenterology* 1998;114:153–163.
- [68] Matsumura T, Takesue M, Westerman KA, Okitsu T, Sakaguchi M, Fukazawa T, et al. Establishment of an immortalized human-liver endothelial cell line with SV40T and hTERT. *Transplantation* 2004;77:1357–1365.
- [69] Hering S, Griffin BE, Strauss M. Immortalization of human fetal sinusoidal liver cells by polyoma virus large T antigen. *Exp Cell Res* 1991;195:1–7.
- [70] Maru Y, Yamaguchi S, Takahashi T, Ueno H, Shibuya M. Virally activated Ras cooperates with integrin to induce tubulogenesis in sinusoidal endothelial cell lines. *J Cell Physiol* 1998;176:223–234.
- [71] Saito M, Matsuura T, Masaki T, Maehashi H, Braet F. Study of the reappearance of sieve plate-like pores in immortalized sinusoidal endothelial cells - Effect of actin inhibitor in mixed perfusion cultures. *Comp Hepatol* 2004;3:528.
- [72] Matsuura T, Kawada M, Hasumura S, Nagamori S, Obata T, Yamaguchi M, et al. High density culture of immortalized liver endothelial cells in the radial-flow bioreactor in the development of an artificial liver. *Int J Artif Organs* 1998;21:229–234.
- [73] Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. *Nat Med* 2007;13:1324–1332.
- [74] Kennedy DW, Abkowitz JL. Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. *Blood* 1997;90:986–993.
- [75] Schaffner F, Poper H. Capillarization of hepatic sinusoids in man. *Gastroenterology* 1963;44:239–242.
- [76] Horn T, Christoffersen P, Henriksen JH. Alcoholic liver injury: defenestration in noncirrhotic livers—a scanning electron microscopic study. *Hepatology* 1987;7:77–82.
- [77] Xu B, Broome U, Uzunel M, Nava S, Ge X, Kumagai-Braesch M, et al. Capillarization of hepatic sinusoid by liver endothelial cell-reactive autoantibodies in patients with cirrhosis and chronic hepatitis. *Am J Pathol* 2003;163:1275–1289.
- [78] Martinez-Hernandez A, Martinez J. The role of capillarization in hepatic failure: studies in carbon tetrachloride-induced cirrhosis. *Hepatology* 1991;14:864–874.
- [79] Mori T, Okanoue T, Sawa Y, Hori N, Ohta M, Kagawa K. Defenestration of the sinusoidal endothelial cell in a rat model of cirrhosis. *Hepatology* 1993;17:891–897.
- [80] Warren A, Bertolino P, Benseler V, Fraser R, McCaughan GW, Le Couteur DG. Marked changes of the hepatic sinusoid in a transgenic mouse model of acute immune-mediated hepatitis. *J Hepatol* 2007;46:239–246.
- [81] DeLeve LD, Wang X, Kanel GC, Atkinson RD, McCuskey RS. Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. *Am J Pathol* 2008;173:993–1001.
- [82] Miyao M, Kotani H, Ishida T, Kawai C, Manabe S, Abiru H, et al. Pivotal role of liver sinusoidal endothelial cells in NAFLD/NASH progression. *Lab Invest* 2015;95:1130–1144.
- [83] Marrone G, Shah VH, Gracia-Sancho J. Sinusoidal communication in liver fibrosis and regeneration. *J Hepatol* 2016;65:608–617. <http://dx.doi.org/10.1016/j.jhep.2016.04.018>.
- [84] Gracia-Pagán J-C, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. *J Hepatol* 2012;57:458–461.
- [85] Xie G, Wang X, Wang L, Wang L, Atkinson RD, Kanel GC, et al. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. *Gastroenterology* 2012;142:918–927 e6.
- [86] D'Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. *Hepatology* 2012;56:532–543.
- [87] Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. *Nature* 2011;473:298–307.
- [88] Ehling J, Bartneck M, Wei X, Gremse F, Fech V, Möckel D, et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. *Gut* 2014;63:1960–1971.
- [89] Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension? *J Hepatol* 2010;53:976–980.
- [90] Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. *Gastroenterology* 2008;135:1729–1738.
- [91] Thabut D, Routay C, Lomber G, Shergill U, Glaser K, Huebert R, et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. *Hepatology* 2011;54:573–585.
- [92] Tarantino G, Conca P, Pasanisi F, Ariello M, Mastrolia M, Arena A, et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? *Eur J Gastroenterol Hepatol* 2009;21:504–511.
- [93] Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. *Cytokine* 2012;59:442–449.
- [94] Cayón A, Crespo J, Guerra AR, Pons-Romero F. Gene expression in obese patients with non-alcoholic steatohepatitis. *Rev Esp Enferm Dig* 2008;100:212–218.
- [95] Sahin H, Borkham-Kamphorst E, Kuppe C, Zaldivar MM, Groulx C, Al-samman M, et al. Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. *Hepatology* 2012;55:1610–1619.
- [96] Kaur S, Tripathi D, Dongre K, Garg V, Rooge S, Mukopadhyay A, et al. Increased number and function of endothelial progenitor cells stimulate angiogenesis by resident liver sinusoidal endothelial cells (SECs) in cirrhosis through paracrine factors. *J Hepatol* 2012;57:1193–1198.
- [97] Rautou P-E. Endothelial progenitor cells in cirrhosis: the more, the merrier? *J Hepatol* 2012;57:1163–1165.
- [98] Ding B-S, Cao Z, Lis R, Nolan DJ, Guo P, Simons M, et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. *Nature* 2013;505:97–102.
- [99] Francque S, Laleman W, Verbeke L, Van Steenkiste C, Casteleyn C, Kwanten W, et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. *Lab Invest* 2012;92:1428–1439.
- [100] Pasarín M, La Mura V, Gracia-Sancho J, García-Calderó H, Rodríguez-Villarrupla A, García-Pagán JC, et al. Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. *PLoS One* 2012;7:e32785.
- [101] Marrone G, Russo L, Rosado E, Hide D, García-Cardena G, García-Pagán JC, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. *J Hepatol* 2013;58:98–103.
- [102] Marrone G, Maeso-Díaz R, García-Cardena G, Abalde JG, García-Pagán JC, Bosch J, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. *Gut* 2014. <http://dx.doi.org/10.1136/gutjnl-2014-308338>.
- [103] Abalde JG, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. *Gastroenterology* 2009;136:1651–1658.
- [104] Abalde JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. *Gastroenterology* 2016. <http://dx.doi.org/10.1053/j.gastro.2016.01.004>.
- [105] Sakamoto M. Early HCC: diagnosis and molecular markers. *J Gastroenterol* 2009;44:108–111.
- [106] Semela D, Dufour J-F. Angiogenesis and hepatocellular carcinoma. *J Hepatol* 2004;41:864–880.
- [107] Céraud C, Mogler C, Runge A, Evdokimov K, Lu S, Schledzewski K, et al. Endothelial transdifferentiation in hepatocellular carcinoma: loss of Stabilin-

- 2 expression in peri-tumorous liver correlates with increased survival. *Liver Int* 2013;33:1428–1440.
- [108] Wu LQ, Zhang WJ, Niu JX, Ye LY, Yang ZH, Grau GE, et al. Phenotypic and functional differences between human liver cancer endothelial cells and liver sinusoidal endothelial cells. *J Vasc Res* 2008;45:78–86.
- [109] Zhuang P-Y, Wang J-D, Tang Z-H, Zhou X-P, Quan Z-W, Liu Y-B, et al. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma. *BMC Cancer* 2015;15:830.
- [110] Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. *N Engl J Med* 2008;359:1995–2004.
- [111] Hu J, Srivastava K, Wieland M, Runge A, Mogler C, Besemfelder E, et al. Endothelial cell-derived angiopoietin-2 controls liver regeneration as a spatiotemporal rheostat. *Science* 2014;343:416–419.
- [112] Golse N, Bucur PO, Adam R, Castaing D, Sa Cunha A, Vibert E. New paradigms in post-hepatectomy liver failure. *J Gastrointest Surg* 2013;17:593–605.
- [113] Yamanaka K, Hatano E, Narita M, Kitamura K, Yanagida A, Asechi H, et al. Olprinone attenuates excessive shear stress through up-regulation of endothelial nitric oxide synthase in a rat excessive hepatectomy model. *Liver Transpl* 2011;17:60–69.
- [114] Schoen JM, Wang HH, Minuk GY, Lauth WW. Shear stress-induced nitric oxide release triggers the liver regeneration cascade. *Nitric Oxide* 2001;5:453–464.
- [115] Sugawara Y, Yamamoto J, Shimada K, Yamasaki S, Kosuge T, Takayama T, et al. Splenectomy in patients with hepatocellular carcinoma and hypersplenism. *J Am Coll Surg* 2000;190:446–450.
- [116] Sato Y, Kobayashi T, Nakatsuka H, Yamamoto S, Oya H, Watanabe T, et al. Splenic arterial ligation prevents liver injury after a major hepatectomy by a reduction of surplus portal hypertension in hepatocellular carcinoma patients with cirrhosis. *Hepatogastroenterology* 2001;48:831–835.
- [117] Troisi R, Cammu G, Militerno G, De Baerdemaeker L, Decruyenaere J, Hoste E, et al. Modulation of portal graft inflow: a necessity in adult living-donor liver transplantation? *Ann Surg* 2003;237:429–436.
- [118] Ito K, Ozasa H, Horikawa S. Effects of prior splenectomy on remnant liver after partial hepatectomy with Pringle maneuver in rats. *Liver Int* 2005;25:438–444.
- [119] Ren Y-S, Qian N-S, Tang Y, Liao Y-H, Liu W-H, Raut V, et al. Beneficial effects of splenectomy on liver regeneration in a rat model of massive hepatectomy. *Hepatobiliary Pancreat Dis Int* 2012;11:60–65.
- [120] Mogl MT, Nüssler NC, Presser SJ, Podrabsky P, Denecke T, Grieser C, et al. Evolving experience with prevention and treatment of splenic artery syndrome after orthotopic liver transplantation. *Transpl Int* 2010;23:831–841.
- [121] Yoshizumi T, Taketomi A, Soejima Y, Ikegami T, Uchiyama H, Kayashima H, et al. The beneficial role of simultaneous splenectomy in living donor liver transplantation in patients with small-for-size graft. *Transpl Int* 2008;21:833–842.
- [122] Yamanaka K, Hatano E, Iguchi K, Yamamoto G, Sato M, Toriguchi K, et al. Effect of olprinone on liver microstructure in rat partial liver transplantation. *J Surg Res* 2013;183:391–396.
- [123] Iguchi K, Hatano E, Yamanaka K, Sato M, Yamamoto G, Kasai Y, et al. Hepatoprotective effect by pretreatment with olprinone in a swine partial hepatectomy model. *Liver Transpl* 2014;20:838–849.
- [124] LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber H-P, et al. Endothelial protection of liver: role of VEGFR-1. *Cancer Cell* 2002;1:229.
- [125] Meyer J, Lejmi E, Fontana P, Morel P, Gonelle-Gispert C, Bühler L. A focus on the role of platelets in liver regeneration: Do platelet-endothelial cell interactions initiate the regenerative process? *J Hepatol* 2015;63:1263–1271.
- [126] Myronovych A, Murata S, Chiba M, Matsuo R, Ikeda O, Watanabe M, et al. Role of platelets on liver regeneration after 90% hepatectomy in mice. *J Hepatol* 2008;49:363–372.
- [127] Murata S, Hashimoto I, Nakano Y, Myronovych A, Watanabe M, Ohkohchi N. Single administration of thrombopoietin prevents progression of liver fibrosis and promotes liver regeneration after partial hepatectomy in cirrhotic rats. *Ann Surg* 2008;248:821–828.
- [128] Matsuo R, Nakano Y, Ohkohchi N. Platelet administration via the portal vein promotes liver regeneration in rats after 70% hepatectomy. *Ann Surg* 2011;253:759–763.
- [129] Melgar-Lesmes P, Edelman ER. Monocyte-endothelial cell interactions in the regulation of vascular sprouting and liver regeneration in mouse. *J Hepatol* 2015;63:917–925.
- [130] Peralta C, Jiménez-Castro MB, Gracia-Sancho J. Hepatic ischemia and reperfusion injury: effects on the liver sinusoidal milieu. *J Hepatol* 2013;59:1094–1106.
- [131] Lalor PF, Shields P, Grant A, Adams DH. Recruitment of lymphocytes to the human liver. *Immunol Cell Biol* 2002;80:52–64.
- [132] Shetty S, Weston CJ, Oo YH, Westerlund N, Stamataki Z, Youster J, et al. Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium. *J Immunol* 1950;2011:4147–4155.
- [133] Limmer A, Ohl J, Kurts C, Ljunggren HG, Reiss Y, Groettrup M, et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. *Nat Med* 2000;6:1348–1354.
- [134] Carambia A, Freund B, Schwinge D, Heine M, Laschtowitz A, Huber S, et al. TGF- β -dependent induction of CD4⁺CD25⁺Foxp3⁺ Tregs by liver sinusoidal endothelial cells. *J Hepatol* 2014;61:594–599.
- [135] Carambia A, Freund B, Schwinge D, Bruns OT, Salmen SC, Ittrich H, et al. Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice. *J Hepatol* 2015;62:1349–1356.
- [136] Neumann K, Rudolph C, Neumann C, Janke M, Amsen D, Scheffold A. Liver sinusoidal endothelial cells induce immunosuppressive IL-10-producing Th1 cells via the Notch pathway. *Eur J Immunol* 2015;45:2008–2016.
- [137] Breiner KM, Schaller H, Knolle PA. Endothelial cell-mediated uptake of a hepatitis B virus: a new concept of liver targeting of hepatotropic microorganisms. *Hepatology* 2001;34:803–808.
- [138] Cormier EG, Durso RJ, Tsamis F, Boussemart L, Manix C, Olson WC, et al. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. *Proc Natl Acad Sci U S A* 2004;101:14067–14072.
- [139] Liu B, Wang M, Wang X, Zhao D, Liu D, Liu J, et al. Liver sinusoidal endothelial cell lectin inhibits CTL-dependent virus clearance in mouse models of viral hepatitis. *J Immunol* 1950;2013:4185–4195.
- [140] Bruns T, Zimmermann HW, Pachnio A, Li K-K, Trivedi PJ, Reynolds G, et al. CMV infection of human sinusoidal endothelium regulates hepatic T cell recruitment and activation. *J Hepatol* 2015;63:38–49.
- [141] Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. *Hepatology* 2010;51:210–218.
- [142] Leong SS, Cazen RA, Yu GS, LeFevre L, Carson JW. Abdominal visceral peliosis associated with bacillary angiomatosis. Ultrastructural evidence of endothelial destruction by bacilli. *Arch Pathol Lab Med* 1992;116:866–871.
- [143] Malamut G, Ziol M, Suarez F, Beaugrand M, Viallard JF, Lascaux AS, et al. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. *J Hepatol* 2008;48:74–82.
- [144] Brunt EM, Gouw ASH, Hubscher SG, Tiniakos DG, Bedossa P, Burt AD, et al. Pathology of the liver sinusoids. *Histopathology* 2014;64:907–920.
- [145] Parent R, Durantel D, Lahlali T, Sallé A, Plissonnier M-L, DaCosta D, et al. An immortalized human liver endothelial sinusoidal cell line for the study of the pathobiology of the liver endothelium. *Biochem Biophys Res Commun* 2014;450:7–12.
- [146] Cogger VC, Arias IM, Warren A, McMahon AC, Kiss DL, Avery VM, et al. The response of fenestrations, actin, and caveolin-1 to vascular endothelial growth factor in SK Hep1 cells. *Am J Physiol Gastrointest Liver Physiol* 2008;295:G137–G145.
- [147] Zhao X, Zhao Q, Luo Z, Yu Y, Xiao N, Sun X, et al. Spontaneous immortalization of mouse liver sinusoidal endothelial cells. *Int J Mol Med* 2015;35:617–624.
- [148] Huebert RC, Jagavelu K, Liebl AF, Huang BQ, Splinter PL, LaRusso NF, et al. Immortalized liver endothelial cells: a cell culture model for studies of motility and angiogenesis. *Lab Invest* 2010;90:1770–1781.
- [149] Terry RW, Kwee L, Baldwin HS, Labow MA. Cre-mediated generation of a VCAM-1 null allele in transgenic mice. *Transgenic Res* 1997;6:349–356.
- [150] Gustafsson E, Brakebusch C, Hietanen K, Fässler R. Tie-1-directed expression of Cre recombinase in endothelial cells of embryoid bodies and transgenic mice. *J Cell Sci* 2001;114:671–676.
- [151] Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. *Dev Biol* 2001;230:230–242.
- [152] Licht AH, Raab S, Hofmann U, Breier E. Endothelium-specific Cre recombinase activity in flk-1-Cre transgenic mice. *Dev Dyn* 2004;229:312–318.
- [153] Forde A, Constien R, Gröne H-J, Hämmerling G, Arnold B. Temporal Cre-mediated recombination exclusively in endothelial cells using Tie2 regulatory elements. *Genes* 2000;2002:191–197.

- [154] Göthert JR, Gustin SE, van Eekelen JAM, Schmidt U, Hall MA, Jane SM, et al. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. *Blood* 2004;104:1769–1777.
- [155] Monvoisin A, Alva JA, Hofmann JJ, Zovein AC, Lane TF, Iruela-Arispe ML. VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium. *Dev Dyn* 2006;235:3413–3422.
- [156] Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. *Nature* 2010;465:483–486.
- [157] Claxton S, Kostourou V, Jadeja S, Chambon P, Hodivala-Dilke K, Fruttiger M. Efficient, inducible Cre-recombinase activation in vascular endothelium. *Genes* 2000;2008:74–80.
- [158] Ehling M, Adams S, Benedito R, Adams RH. Notch controls retinal blood vessel maturation and quiescence. *Development* 2013;140:3051–3061.
- [159] Sano N, Tamura T, Toriyabe N, Nowatari T, Nakayama K, Tanoi T, et al. New drug delivery system for liver sinusoidal endothelial cells for ischemia-reperfusion injury. *World J Gastroenterol* 2015;21:12778–12786.
- [160] Fraser JR, Alcorn D, Laurent TC, Robinson AD, Ryan GB. Uptake of circulating hyaluronic acid by the rat liver. Cellular localization in situ. *Cell Tissue Res* 1985;242:505–510.
- [161] Toriyabe N, Hayashi Y, Hyodo M, Harashima H. Synthesis and evaluation of stearylated hyaluronic acid for the active delivery of liposomes to liver endothelial cells. *Biol Pharm Bull* 2011;34:1084–1089.
- [162] Takei Y, Maruyama A, Ferdous A, Nishimura Y, Kawano S, Ikejima K, et al. Targeted gene delivery to sinusoidal endothelial cells: DNA nanoassociate bearing hyaluronan-glycocalyx. *FASEB J* 2004;18:699–701.
- [163] Kren BT, Unger GM, Sjeklocha L, Trossen AA, Korman V, Diethelm-Okita BM, et al. Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. *J Clin Invest* 2009;119:2086–2099.
- [164] Tanoi T, Tamura T, Sano N, Nakayama K, Fukunaga K, Zheng Y-W, et al. Protecting liver sinusoidal endothelial cells suppresses apoptosis in acute liver damage. *Hepatol Res* 2015. <http://dx.doi.org/10.1111/hepr.12607>.
- [165] Akhter A, Hayashi Y, Sakurai Y, Ohga N, Hida K, Harashima H. Ligand density at the surface of a nanoparticle and different uptake mechanism: two important factors for successful siRNA delivery to liver endothelial cells. *Int J Pharm* 2014;475:227–237.
- [166] Bartsch M, Weeke-Klimp AH, Meijer DKF, Scherphof GL, Kamps JAAM. Massive and selective delivery of lipid-coated cationic lipoplexes of oligonucleotides targeted in vivo to hepatic endothelial cells. *Pharm Res* 2002;19:676–680.
- [167] Kamps JA, Morselt HW, Swart PJ, Meijer DK, Scherphof GL. Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells. *Proc Natl Acad Sci U S A* 1997;94:11681–11685.
- [168] Bartsch M, Weeke-Klimp AH, Morselt HWM, Kimpfler A, Asgeirsdóttir SA, Schubert R, et al. Optimized targeting of polyethylene glycol-stabilized anti-intercellular adhesion molecule 1 oligonucleotide/lipid particles to liver sinusoidal endothelial cells. *Mol Pharmacol* 2005;67:883–890.
- [169] Sato Y, Hatakeyama H, Sakurai Y, Hyodo M, Akita H, Harashima H. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. *J Control Release* 2012;163:267–276.
- [170] Enzan H, Himeno H, Hiroi M, Kiyoku H, Saibara T, Onishi S. Development of hepatic sinusoidal structure with special reference to the Ito cells. *Microsc Res Tech* 1997;39:336–349.
- [171] Herrnberger L, Hennig R, Kremer W, Hellerbrand C, Goepferich A, Kalbitzer HR, et al. Formation of fenestrae in murine liver sinusoids depends on plasmalemma vesicle-associated protein and is required for lipoprotein passage. *PLoS One* 2014;9:e115005.